|1.||Hibbitts, Sarah: 2 articles (11/2004 - 11/2004)|
|2.||Slingluff, Craig L: 2 articles (11/2004 - 11/2004)|
|3.||Deacon, Donna H: 2 articles (11/2004 - 11/2004)|
|4.||Chianese-Bullock, Kimberly A: 2 articles (11/2004 - 11/2004)|
|5.||Cavazza, Antonella: 2 articles (03/2004 - 03/2003)|
|6.||Marini, Mario: 2 articles (03/2004 - 03/2003)|
|7.||Albo, Federica: 2 articles (03/2004 - 03/2003)|
|8.||Giardina, Bruno: 2 articles (03/2004 - 03/2003)|
|9.||Roda, L Giorgio: 2 articles (03/2004 - 03/2003)|
|10.||Grosh, W W: 2 articles (10/2001 - 06/2001)|
|1.||Melanoma (Melanoma, Malignant)
05/05/1999 - "As a model system, we used SCID mice bearing an s.c.-implanted human melanoma line (BLM-gp100) and in vitro-generated CTL specific for the gp100-derived immunogenic peptide YLEPGPVTA, which were injected i.v. with delay. "
10/01/2001 - "A melanoma vaccine composed of HLA-A2-restricted peptide YLEPGPVTA (gp100(280)), with or without a modified T-helper epitope from tetanus toxoid AQYIKANSKFIGITEL, has been evaluated in a Phase I trial to assess safety and immunological response. "
10/15/1996 - "In this study, peripheral blood mononuclear cells (PBMCs) were harvested from HLA-A2+ melanoma patients before and after immunization with G9-209 (ITDQVPFSY), G9-280 (YLEPGPVTA), or G9-154 (KTWGQYWQV) peptides in Incomplete Freund's Adjuvant and were tested for the ability to be sensitized in vitro using PBMCs pulsed with the native peptides. "
08/27/1999 - "HLA-A*0201-restricted CTLs from one melanoma patient who has survived metastatic disease recognized MART-1(27-35) (AAGIGILTV), gp100(280-288) (YLEPGPVTA) and gp100(154-162) (KTWGQYWQV) and were cross-reactive on longer peptides that contained these nonamer sequences. "
11/15/2004 - "T-cell responses to the melanoma peptides were observed in 37% of PBL and 38% of SINs in group 1, and in 53% of PBL and 83% of SINs in group 2. The magnitude of T-cell response was higher in group 2. The tyrosinase peptides DAEKSDICTDEY and YMDGTMSQV were more immunogenic than the gp100 peptides YLEPGPVTA and ALLAVGATK. "
03/17/2004 - "Degradation of the tumor antigen epitope gp100(280-288) (YLEPGPVTA) was investigated in the presence of cultured human fibroblasts, and acellular supernatants obtained from these cells; the possible effect of substrate degradation on in vitro immunorecognition was also addressed. "
03/01/2003 - "The possible degradation of the tumor antigen epitope gp100(280-288) (YLEPGPVTA) in the presence of the monocyte-like line U937, and the effect of degradation on the in vitro-measured immune recognition, were investigated by chromatographic techniques and immunological assays. "
|2.||Tetanus Toxoid (Vaccine, Tetanus)
|3.||incomplete Freund's adjuvant
|4.||Monophenol Monooxygenase (Tyrosinase)
|5.||HLA-A2 Antigen (HLA A2 Antigen)
|10.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)